Robert W. Ross is CEO at Surface Oncology, Inc. (SURF). They have made 4 open-market trades across 1 company since 2020, most recently 2023-09-08.
CIK 0001733077
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SURF | 83,193 | $89K |
Shares reported on the most recent Form 4, priced at the 2023-08-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SURF | SELL | 2023-08-01 | 2023-08-11 | $0.94 | $16K | +3.0% | N/A | N/A |
| SURF | SELL | 2022-08-03 | 2022-08-05 | $1.72 | $18K | -1.1% | -25.7% | -31.3% |
| SURF | SELL | 2021-07-21 | 2022-01-14 | $6.10 | $204K | -18.5% | -16.4% | -39.6% |
| SURF | SELL · 10b5-1 | 2021-02-16 | 2021-02-18 | $11.35 | $11K | -7.1% | -1.6% | -11.1% |
| SURF | SELL | 2021-01-14 | 2021-01-15 | $12.02 | $108K | -16.1% | -15.3% | -44.9% |
| SURF | SELL · 10b5-1 | 2020-12-15 | 2020-12-17 | $10.48 | $10K | +2.5% | +42.0% | -3.6% |
| SURF | SELL · 10b5-1 | 2020-12-11 | 2020-12-15 | $10.05 | $14K | -10.5% | +18.3% | -12.1% |
| SURF | SELL · 10b5-1 | 2020-11-11 | 2020-11-13 | $10.05 | $6K | -12.3% | +18.6% | +29.0% |
| SURF | SELL · 10b5-1 | 2020-10-14 | 2020-10-16 | $10.05 | $40K | -8.4% | -15.2% | +26.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.